| |
Thursday, February 20, 2025 | 2pm ET / 11am PT Clinical trials only continue to increase in complexity. Join industry experts to explore how AI can transform workflows to help sponsors and CROs better manage data while maintaining speed, quality and compliance. Register now. 
|
|
Today’s Big NewsJan 31, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now. 
|
|
| By James Waldron Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. |
|
|
|
By James Waldron Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. |
By Andrea Park,Gabrielle Masson This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
Sponsored by Salesforce Drug development and commercialization leads to tremendous advances in medicine and improvements to everyday life, but it often comes at a cost. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
By Angus Liu The rising class of bispecifics opened up an opportunity for the Swiss pharma to re-enter the PD-1 space from a new angle. The question is: Will the company take it? CEO Vas Narasimhan has weighed in. |
By Nick Paul Taylor Kadimastem’s attempt to vault onto Nasdaq is picking up momentum, with shareholders signing off on a merger with NLS Pharmaceutics that would enable the cell therapy developer to recover from last year’s thwarted listing attempt. |
By Darren Incorvaia,Zoey Becker After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will be replaced by Julie Kim, who came to Takeda in 2019 with the company’s $62 billion acquisition of Shire. |
By Darren Incorvaia An antibody that can bind to many different types of influenza virus prevented macaques from getting seriously sick, and dying, from a highly pathogenic strain of H5N1 bird flu. |
By Zoey Becker Sens. Bill Cassidy, R-Louisiana, and Bernie Sanders, I-Vermont, presented a bipartisan united front as they grilled RFK Jr. on his past claims that vaccines cause autism. |
By Kevin Dunleavy Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation in pain relief in more than two decades. |
By Dave Muoio The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program. In response, Senate Democrats pushed HHS secretary nominee Robert F. Kennedy Jr. for reassurances that the program is safe from drugmakers' lobbying. |
By Fraiser Kansteiner GE HealthCare is pumping $138 million into its Carrigtwohill fill-finish site in County Cork, for a facility that will help deliver 25 million more contrast media doses per year by the end of 2027, including commercial products and those in the pipeline. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
